Spark Therapeutics, Inc. (NASDAQ:ONCE) – Cantor Fitzgerald issued their FY2016 earnings per share estimates for Spark Therapeutics in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst E. Piros anticipates that the firm will post earnings per share of ($4.19) for the year. Cantor Fitzgerald has a “Buy” rating and a $94.00 price target on the stock. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2017 earnings at ($4.44) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business earned $1.30 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. The firm’s quarterly revenue was up .0% on a year-over-year basis. TRADEMARK VIOLATION WARNING: “Spark Therapeutics, Inc. Forecasted to Earn FY2016 Earnings of ($4.19) Per Share (ONCE)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at http://www.watchlistnews.com/spark-therapeutics-inc-forecasted-to-earn-fy2016-earnings-of-4-19-per-share-once/1061081.html.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

A number of other equities research analysts have also commented on ONCE. Zacks Investment Research lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Group reaffirmed a “hold” rating and issued a $57.00 price objective on shares of Spark Therapeutics in a research note on Tuesday. Chardan Capital reaffirmed a “neutral” rating and issued a $47.50 price objective (down from $55.00) on shares of Spark Therapeutics in a research note on Monday, November 7th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Monday, November 7th. Finally, BMO Capital Markets initiated coverage on shares of Spark Therapeutics in a research note on Tuesday, December 20th. They issued an “outperform” rating and a $69.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $60.69.

Shares of Spark Therapeutics (NASDAQ:ONCE) opened at 57.13 on Friday. Spark Therapeutics has a 52 week low of $21.20 and a 52 week high of $65.99. The firm’s market capitalization is $1.76 billion. The firm has a 50-day moving average of $53.39 and a 200 day moving average of $55.20.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its position in Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock valued at $124,000 after buying an additional 299 shares during the last quarter. Legal & General Group Plc increased its position in Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock valued at $138,000 after buying an additional 1,394 shares during the last quarter. Great West Life Assurance Co. Can increased its position in Spark Therapeutics by 113.5% in the third quarter. Great West Life Assurance Co. Can now owns 2,675 shares of the company’s stock valued at $160,000 after buying an additional 1,422 shares during the last quarter. SG Americas Securities LLC acquired a new position in Spark Therapeutics during the third quarter valued at $188,000. Finally, Argentus Capital Management LLC acquired a new position in Spark Therapeutics during the third quarter valued at $293,000. Hedge funds and other institutional investors own 82.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics, Inc. Forecasted to Earn FY2016 Earnings of ($4.19) Per Share (ONCE)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at http://www.watchlistnews.com/spark-therapeutics-inc-forecasted-to-earn-fy2016-earnings-of-4-19-per-share-once/1061081.html.

In other Spark Therapeutics news, insider Barge Joseph La sold 3,000 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $52.98, for a total transaction of $158,940.00. Following the transaction, the insider now owns 8,325 shares in the company, valued at $441,058.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the company’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $54.66, for a total transaction of $273,300.00. Following the transaction, the chief executive officer now owns 235,000 shares in the company, valued at approximately $12,845,100. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.